Institutional Ownership
Corbus Pharmaceuticals Hldgs
CUSIP 21833P301COM NEWCRBPQ1 2026
13D / 13G Filings
31
Schedule 13D/13G on record
Beneficial Filers
20
Distinct reporting persons
Largest Stake
19.5%
Max % of class reported
Institutional Holders
102
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
31 filings · latest Feb 10, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 10, 2026 | Octagon Capital Advisors LP | 13G/A | 5.4% | 955.0K | SEC |
| 2 | Jan 16, 2026 | Aberdeen Group PLC | 13G | 7.5% | 1.32M | SEC |
| 3 | Dec 15, 2025 | Cormorant Asset Management, LP | 13G/A | 13.4% | 2.34M | SEC |
| 4 | Nov 14, 2025 | Cormorant Asset Management, LP | 13G/A | 12.8% | 2.38M | SEC |
| 5 | Nov 12, 2025 | Citadel Advisors LLC | 13G | 5.3% | 980.6K | SEC |
| 6 | Jul 29, 2025 | The Vanguard Group | 13G/A | 4.9% | 599.5K | SEC |
| 7 | Jul 16, 2025 | Blackrock, Inc. | 13G/A | 2.9% | 352.4K | SEC |
| 8 | Feb 14, 2025 | Orbimed Advisors LLC | 13G/A | 5.9% | 454.09B | SEC |
| 9 | Nov 14, 2024 | Tang Capital Management LLC | 13G/A | 5.0% | 600.0K | SEC |
| 10 | Nov 14, 2024 | Cormorant Asset Management, LP | 13G/A | 19.5% | 2.38M | SEC |
21 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Corbus Pharmaceuticals Hldgs.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Cormorant Asset Management, LP | 2.34M | $22.02M |
| 2 | Orbimed Advisors LLC | 1.74M | $16.31M |
| 3 | Aberdeen Group PLC | 1.32M | $12.41M |
| 4 | Citadel Advisors LLC | 727.1K | $6.83M |
| 5 | Prosight Management, LP | 697.1K | $6.55M |
| 6 | Diadema Partners LP | 440.0K | $4.13M |
| 7 | Stonepine Capital Management, LLC | 383.5K | $3.60M |
| 8 | Armistice Capital, LLC | 364.0K | $3.42M |
| 9 | Renaissance Technologies LLC | 347.0K | $3.26M |
| 10 | Susquehanna International Group, LLP | 333.4K | $3.13M |